The purpose of this research is to assess the efficacy of Platelet-Rich Fibrin (PRF) in the regeneration of periodontal tissues in patients suffering from periodontal disease. Periodontal disease is a chronic inflammatory disease that affects the gums and the bone supporting the teeth, which can eventually result in the loss of teeth if left untreated. Conventional periodontal treatment can control the infection and halt the progression of the disease but cannot reverse the loss of the supporting structures.

Platelet-Rich Fibrin is a biologic material derived from a small amount of the patient's own blood. It has growth factors that can potentially enhance healing and facilitate the regeneration of bone and soft tissues. In this randomized controlled clinical trial, patients will be randomly assigned to either conventional periodontal surgical treatment or conventional treatment along with PRF.

Over a predetermined follow-up period, clinical measurements like gum pocket depth, attachment levels, and radiographic bone changes will be assessed to see if PRF offers any extra advantages in tissue healing and regeneration. The results of this study could improve long-term oral health outcomes and periodontal disease treatment approaches.

Periodontal disease is marked by the inflammation-mediated loss of the supporting structures of the teeth, leading to the formation of periodontal pockets, loss of clinical attachment, and resorption of the alveolar bone. The regenerative aspect of periodontal therapy aims at the replacement of these lost structures to improve the stability of the teeth and their functional status in the oral environment. Platelet-Rich Fibrin (PRF), an autologous platelet concentrate derived from the centrifugation of the patient's blood, is a fibrin matrix rich in growth factors that could potentially improve wound healing, angiogenesis, and bone regeneration.

The aim of this randomized controlled clinical trial is to assess the additional role of PRF when used in combination with conventional periodontal surgical therapy compared to conventional therapy alone in patients diagnosed with periodontal defects that require surgical treatment. The participants will be randomly assigned into two groups. The control group will undergo conventional periodontal surgical therapy, while the intervention group will undergo the same surgical therapy plus PRF. The procedures will be carried out according to standardized clinical protocols to ensure uniformity among the participants.

The clinical outcomes will be measured by changes in pocket depth, clinical attachment level, and other periodontal parameters. Radiographic analysis will also be conducted to evaluate bone fill and regenerative outcomes at specific intervals. The safety of the procedure will be continuously monitored, and since the PRF is autologous, the risk of immunologic reaction is minimal.

This study will offer high-quality evidence on the effectiveness of PRF as a regenerative tool in periodontal therapy and may help in making better clinical decisions in the treatment of periodontal defects.

Inclusion Criteria:

• Adults aged 18-65 years. Diagnosed with chronic periodontitis according to standard clinical criteria. Presence of periodontal intrabony defects suitable for surgical intervention. Probing pocket depth (PPD) ≥ 5 mm at the target site. Clinical attachment level (CAL) loss ≥ 3 mm at the target site. Good oral hygiene, with full-mouth plaque score < 25%.

Exclusion Criteria:

• Patients with systemic diseases that affect healing (e.g., uncontrolled diabetes, immunodeficiency).

Pregnant or lactating women. Current smokers or tobacco users. History of periodontal surgery at the target site within the last 12 months. Use of medications that interfere with wound healing (e.g., corticosteroids, bisphosphonates).

Allergies or contraindications to local anesthetics or components used in the study.

Active oral infections or untreated caries at or near the target site.

Many single-center clinical trials, especially in dentistry, do not share IPD publicly.

Sharing IPD requires additional ethical approval, consent language, and data management plans.